180 related articles for article (PubMed ID: 37166579)
21. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial.
Major T; Polgár C; Jorgo K; Stelczer G; Ágoston P
Brachytherapy; 2017; 16(3):608-615. PubMed ID: 28325472
[TBL] [Abstract][Full Text] [Related]
22. MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life.
Maenhout M; Peters M; Moerland MA; Meijer RP; van den Bosch MAAJ; Frank SJ; Nguyen PL; van Vulpen M; van der Voort van Zyp JRN
Radiother Oncol; 2018 Dec; 129(3):554-560. PubMed ID: 30131183
[TBL] [Abstract][Full Text] [Related]
23. Second primary malignancies after radiotherapy including HDR (252)Cf brachytherapy for cervical cancer.
Samerdokiene V; Valuckas KP; Janulionis E; Atkocius V; Rivard MJ
Brachytherapy; 2015; 14(6):898-904. PubMed ID: 26194049
[TBL] [Abstract][Full Text] [Related]
24. Accuracy assessment of a potential clinical use of navigation-guided intra-operative liver metastasis brachytherapy-a planning study.
Herrmann E; Terribilini D; Manser P; Fix MK; Toporek G; Candinas D; Weber S; Aebersold DM; Loessl K
Strahlenther Onkol; 2018 Nov; 194(11):1030-1038. PubMed ID: 30022277
[TBL] [Abstract][Full Text] [Related]
25. The Curie-Da Vinci Connection: 5-Years' Experience With Laparoscopic (Robot-Assisted) Implantation for High-Dose-Rate Brachytherapy of Solitary T2 Bladder Tumors.
van der Steen-Banasik EM; Smits GAHJ; Oosterveld BJ; Janssen T; Visser AG
Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1439-1442. PubMed ID: 27296041
[TBL] [Abstract][Full Text] [Related]
26. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience.
Aluwini S; van Rooij PH; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1480-5. PubMed ID: 22285661
[TBL] [Abstract][Full Text] [Related]
27. Acute toxicity and health-related quality of life outcomes of localized prostate cancer patients treated with magnetic resonance imaging-guided high-dose-rate brachytherapy: A prospective phase II trial.
Sanmamed N; Adleman J; Berlin A; Borg J; Lao B; Weersink R; Simeonov A; Rink A; Beiki-Ardakani A; Menard C; Chung P; Helou J
Brachytherapy; 2023; 22(1):58-65. PubMed ID: 36414526
[TBL] [Abstract][Full Text] [Related]
28. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation.
Ricke J; Wust P; Wieners G; Beck A; Cho CH; Seidensticker M; Pech M; Werk M; Rosner C; Hänninen EL; Freund T; Felix R
J Vasc Interv Radiol; 2004 Nov; 15(11):1279-86. PubMed ID: 15525748
[TBL] [Abstract][Full Text] [Related]
29. Urethral dosimetry and toxicity with high-dose-rate interstitial brachytherapy for vaginal cancer.
Rajagopalan MS; Kannan N; Kim H; Houser CJ; Beriwal S
Brachytherapy; 2013; 12(3):248-53. PubMed ID: 23453679
[TBL] [Abstract][Full Text] [Related]
30. Outcome analysis of HDR compared to PDR IGABT in locally advanced cervical cancer: a single-center cohort analysis.
Hermesse J; Pleyers C; Gennigens C; De Cuypere M; Lovinfosse P; Seidel Statistician L; Coucke P; Kridelka F
Strahlenther Onkol; 2023 Feb; 199(2):141-148. PubMed ID: 35943555
[TBL] [Abstract][Full Text] [Related]
31. From low-dose-rate to high-dose-rate brachytherapy in lip carcinoma: Equivalent results but fewer complications.
Guinot JL; Arribas L; Tortajada MI; Crispín V; Carrascosa M; Santos M; Mut A; Vendrell JB; Pesudo C; Chust ML
Brachytherapy; 2013; 12(6):528-34. PubMed ID: 23850275
[TBL] [Abstract][Full Text] [Related]
32. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
Pellizzon AC; Salvajoli J; Novaes P; Maia M; Fogaroli R; Gides D; Horriot R
Int J Med Sci; 2008 Jun; 5(3):113-20. PubMed ID: 18566673
[TBL] [Abstract][Full Text] [Related]
33. Gantry-Based 5-Fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes From 2 Prospective Studies Comparing SABR Boost With MR Dose-Painted HDR Brachytherapy Boost.
Musunuru HB; Cheung P; Vesprini D; Liu SK; Chu W; Chung HT; Morton G; Deabreu A; Davidson M; Ravi A; Helou J; Ho L; Zhang L; Loblaw A
Int J Radiat Oncol Biol Phys; 2022 Mar; 112(3):735-743. PubMed ID: 34637882
[TBL] [Abstract][Full Text] [Related]
34. Interstitial hyperthermia of the prostate in combination with brachytherapy : An evaluation of feasibility and early tolerance.
Kukiełka AM; Hetnał M; Brandys P; Walasek T; Dąbrowski T; Pluta E; Nahajowski D; Kudzia R
Strahlenther Onkol; 2013 Jun; 189(6):467-75. PubMed ID: 23604184
[TBL] [Abstract][Full Text] [Related]
35. Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.
Aluwini S; Busser WM; Alemayehu WG; Boormans JL; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
Radiother Oncol; 2015 Nov; 117(2):252-7. PubMed ID: 26409832
[TBL] [Abstract][Full Text] [Related]
36. Treatment of cervical cancer with electronic brachytherapy.
Lozares-Cordero S; Font-Gómez JA; Gandía-Martínez A; Miranda-Burgos A; Méndez-Villamón A; Villa-Gazulla D; Alba-Escorihuela V; Jiménez-Puertas S; González-Pérez V
J Appl Clin Med Phys; 2019 Jul; 20(7):78-86. PubMed ID: 31183970
[TBL] [Abstract][Full Text] [Related]
37. In vivo assessment of catheter positioning accuracy and prolonged irradiation time on liver tolerance dose after single-fraction 192Ir high-dose-rate brachytherapy.
Lüdemann L; Wybranski C; Seidensticker M; Mohnike K; Kropf S; Wust P; Ricke J
Radiat Oncol; 2011 Sep; 6():107. PubMed ID: 21892943
[TBL] [Abstract][Full Text] [Related]
38. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
[TBL] [Abstract][Full Text] [Related]
39. High-dose-rate interstitial brachytherapy vs external beam radiation for the treatment of complex keloids.
Liao Y; Dorafshar AH; Bernard D; Kim T; Camden NB; Wang D
Med Dosim; 2022 Summer; 47(2):158-160. PubMed ID: 35264302
[TBL] [Abstract][Full Text] [Related]
40. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
